U.S. Home Infusion Therapy Market Size, Share & Industry Analysis, By Product (Devices {Durable Medical Equipment/Pumps and Consumables & Accessories}, Drugs {Small Molecule/Conventional Infused Drugs, Biologics & Plasma-Derived Therapies, and Nutrition Products}, and Services {Pharmacy Services, Nursing & Clinical Services, Logistic & Care Coordination, and Training & Monitoring Services}), By Indication (Enteral Nutrition, Anti-Infective, Chemotherapy, Hydration Therapy, Total Parenteral Nutrition, Immunoglobulins, and Others), and Regional Forecast, 2026-2034

The U.S. home infusion therapy market size was valued at USD 21.52 billion in 2025. The market is projected to grow from USD 23.58 billion in 2026 to USD 49.83 billion by 2034, exhibiting a CAGR of 9.81% during the forecast period.

The U.S. market includes infusion drugs, devices, consumables, and services used to administer intravenous or subcutaneous therapies in a patient’s homecare setting. The market growth is driven by the rising need to shift eligible patients from hospitals to lower-cost home based care, increasing use of specialty infused drugs, growing demand for immunoglobulin and nutrition support, and the need for long-term management of chronic and complex diseases.

Prominent firms in the U.S. market include Option Care Health Inc., Optum Inc., and CVS Health. These companies are strengthening their positions through home infusion pharmacies, ambulatory infusion suites, specialty pharmacy capabilities, nursing support, infusion pumps, administration sets, and digital care coordination platforms.

U.S. Home Infusion Therapy Market Trends

Growing Therapy Diversity and Demand for these Services to be a Significant Market Trend

Growing therapy diversity is becoming a key trend in the market, as providers are moving beyond traditional anti-infective care and supporting a wider mix of home enteral nutrition, parenteral nutrition, immune globulin, specialty infusion, hydration, and other chronic therapies. This is increasing the demand for pharmacy compounding, nursing support, infusion devices, consumables, payer coordination, patient education, and home-based monitoring. The trend is also supported by the rising use of long-term specialty therapies for immune deficiencies, autoimmune disorders, GI diseases, infections, and complex chronic conditions, where patients often prefer lower-cost and more convenient care outside hospitals.

• For instance, in September 2025, NHIA released a white paper highlighted that HEN requires clinical coordination, disease-specific formulas, specialized equipment, and a multidisciplinary team to ensure efficacy, safety, and quality of life.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Burden of Chronic and Complex Diseases Requiring Long-term Infusion Therapy to Drive Market Growth

The increasing incidence of chronic and complex illnesses in the U.S. significantly fuels the home infusion therapy market, as numerous patients need ongoing or prolonged administration of infused medications, biologics, nutritional products, and supportive treatments. Chronic illnesses impact a significant number of individuals which establishes a significant treatment market for therapies targeting cancer, immune deficiencies, autoimmune conditions, neurological issues, gastrointestinal problems, and persistent infections. There is a growing demand for home-based IVIG, anti-infectives, parenteral nutrition, enteral nutrition, hydration support, and specialty biologics, as patients and healthcare providers seek treatment alternatives beyond hospitals. Home infusion aids in enhancing continuity of care for patients requiring extended therapy following hospital discharge or for ongoing management of chronic diseases. All these factors are driving market growth.

• For instance, according to the data published by NIHCM Foundation in April 2025, around 6 in 10 Americans live with at least one chronic disease, creating a large patient base for recurring treatment and long-term care support.

MARKET RESTRAINTS

Clinical Complexity and Patient-safety Risks in Home Setting to Hamper Market Growth

Clinical complexity and patient-safety risks are expected to restrain the growth of the market, as infusion therapy at home requires safe handling of drugs, vascular access devices, pumps, tubing, catheters, and sterile supplies outside a hospital environment. Patients receiving IVIG, TPN, chemotherapy support, anti-infectives, hydration therapy, and specialty biologics may face risks such as infusion reactions, catheter-related infections, dosing errors, pump alarms, and line-care complications. This increases the need for trained nurses, caregiver education, patient monitoring, emergency response planning, and standardized infection-prevention practices, which can raise operating costs and limit the number of patients suitable for home-based therapy.

• For instance, in May 2024, a study published in the infection-prevention literature found that infection prevention and surveillance training approaches for home infusion therapy were not well defined, and identified gaps in formal training for central line-associated bloodstream infection surveillance among home infusion staff. This highlights the need for stronger infection-prevention capabilities as more therapies shift into home settings.

MARKET OPPORTUNITIES

Expansion of Home Infusion Therapy Services to Offer Lucrative Market Opportunities

The expansion of home infusion therapy services is anticipated to generate profitable expansion possibilities in the U.S. market, as providers, payers, and health systems persist in transferring appropriate therapies from hospitals to more affordable home and alternative locations. This growth is bolstered by the increasing need for IVIG, specialty biologics, anti-infectives, parenteral nutrition, enteral nutrition, hydration therapy, and chronic infusion assistance. Home infusion providers are growing via specialty pharmacies, ambulatory infusion centers, nursing networks, and digital coordination platforms to enhance patient access and minimize delays in starting therapy. The opportunity is compelling as home infusion integrates pharmacy dispensing, clinical oversight, nursing services, devices, supplies, and logistics into a single care model, rendering it extremely pertinent for managing long-term and complex diseases. All these factors would drive the U.S. home infusion therapy market growth in the coming years.

• For instance, in November 2025, Reliant Healthcare and Care Fusion Rx merged to form a national infusion therapy platform, with the combined company focused on expanding access to home and ambulatory infusion therapy across the U.S.

MARKET CHALLENGES

Reimbursement Limitations and Fragmented Medicare Coverage to Limit Market Growth

Restrictions on reimbursement and fragmented Medicare coverage continue to pose significant obstacles for the U.S. home infusion therapy sector. As providers need to navigate distinct coverage regulations for medications, pumps, supplies, nursing visits, pharmacy services, and monitoring. This generates ambiguity for home infusion providers and may restrict access for Medicare beneficiaries who might otherwise obtain IV therapies at home. The challenge is particularly significant for anti-infectives, IVIG, TPN, specialty biologics, and other treatments that necessitate pharmacy coordination, compounding, supplies, and clinical oversight that goes beyond a basic nursing appointment. All the factors cumulatively affect the market growth.

• For instance, National Home Infusion Association (NHIA) indicates that the rollout of the Medicare Part B home infusion benefit by CMS has resulted in restricted access and significant access challenges for Medicare beneficiaries, contrary to congressional intent for a thorough home infusion benefit.

Segmentation Analysis

By Product

Drugs Segment Dominated Owing to High Clinical Relevance and Recurring Therapy Demands

Based on product, the market is divided into devices, drugs, and services.

The drugs segment captured the largest U.S. home infusion therapy market share in 2025. The dominance is mainly due to the high use of immunoglobulins, specialty biologics, anti-infectives, chemotherapy drugs, hydration solutions, and parenteral nutrition formulations in home and alternate-site care. These therapies are often required for chronic and complex conditions such as primary immunodeficiency, autoimmune diseases, cancer, GI disorders, infections, and neurological diseases, creating recurring demand for drug-based treatment. In addition, high-cost therapies such as IVIG/SCIG and specialty biologics increase the revenue contribution of the drugs segment. Moreover, the shift of suitable infusion therapies from hospitals to home settings further supports drug utilization, as providers combine specialty pharmacy dispensing with nursing, monitoring, and care coordination.

• For instance, in December 2024, the U.S. FDA approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous injection across approved adult solid tumor indications of nivolumab. This drug could be administered at-home by a qualified health care professional only.

The services segment is anticipated to rise with a CAGR of 10.61% over the forecast period. 

To know how our report can help streamline your business, Speak to Analyst

By Indication

Enteral Nutrition Segment Dominated Owing to High Recurring Need and Broad Home-based Use

Based on indication, the market is classified into anti-infective, enteral nutrition, hydration therapy, chemotherapy, immunoglobulins, total parenteral nutrition, and others.

The enteral nutrition segment captured the highest market share in 2025. As it serves to a substantial number of patients needing long-term nutritional assistance at home owing to dysphagia, neurological issues, cancer, gastrointestinal ailments, and various other chronic conditions. The segment is characterized by high recurrence since patients require a constant supply of enteral formulas, feeding pumps, feeding bags, tubing, syringes, connectors, and assistance with care coordination. In contrast to certain short-term infusion treatments, home enteral nutrition frequently lasts for months or even years, enhancing its impact on the total market value. The segment also benefits from extensive application among pediatric, adult, and elderly patients, particularly when oral intake is inadequate but the gastrointestinal tract is still operational. Additionally, the requirement for nutrition formulas tailored to specific diseases, specialized tools, and a collaborative approach enhances the commercial significance of this indication within the U.S. market.

• For instance, in September 2025, National Home Infusion Association (NHIA) published a Home Enteral Nutrition white paper stating that around 220,000 individuals in the U.S. rely on home enteral nutrition.

The anti-infective segment is growing at a CAGR of 7.30% over the forecast period. 

By Region

West U.S. Segment Dominated Due to Strong Specialty-care Infrastructure and Higher Home-infusion Adoption

On the basis of region, the market is segmented into West U.S., South U.S., Middle West U.S., and Northeast U.S.

The West U.S. segment dominated the U.S in 2025. This is due to the strong presence of advanced healthcare systems, specialty-care providers, home health networks, and higher adoption of home-based chronic therapy models across states such as California, Washington, Arizona, Colorado, Nevada, and Oregon. The region has strong demand for immunoglobulin therapy, enteral nutrition, parenteral nutrition, oncology-support infusion, anti-infective therapy, and other specialty infusions, supported by a large chronic disease patient base and broad payer/provider networks. In addition, the presence of major device, specialty pharmacy, and infusion-service players in western states supports faster access to infusion drugs, pumps, consumables, and clinical services.

• For instance, in July 2023, Eitan Medical launched Eitan Insights, a cloud-based infusion management platform designed for home and specialty infusion providers. The platform enables near-real-time infusion data visibility from Sapphire and Avoset pumps, supporting remote infusion management and connected home-infusion workflows, which aligns with the West U.S. market’s higher adoption of technology-enabled home care.

The South U.S. region is growing at a CAGR of 9.98% over the forecast period. 

COMPETITIVE LANDSCAPE

Key Industry Players

Broad Service Networks and Specialty Infusion Capabilities to Support Players’ Market Position

The U.S. home infusion therapy market reflects a moderately consolidated competitive landscape, consisting of major providers such as Option Care Health, Optum Inc., and CVS Health. The considerable market presence of these companies is owing to their broad service networks, specialty pharmacy capabilities, home infusion pharmacies, and care coordination platforms. Furthermore, these players are focusing on strategic initiatives such as mergers & acquisitions to strengthen their competitive position.

• For instance, in May 2025, KabaFusion acquired infusion care assets from Coram, adding six locations that will serve as pharmacies and ambulatory infusion suites and expanding its footprint to 32 specialty pharmacies and 19 ambulatory infusion suites across 26 states.

Additional key contributors include KabaFusion, CareCentrix, Inc., PromptCare Respiratory, Baxter, InfuSystem Holdings, Inc., and Moog Inc., among others. These players are strengthening their positions through geographic expansion, payer partnerships, specialty therapy breadth, home nursing support, digital referral workflows, and infusion-suite networks to capture the rising demand for home infusion services in the U.S.

LIST OF KEY U.S. HOME INFUSION THERAPY COMPANIES PROFILED IN REPORT

• Option Care Health Inc. (U.S.)
• Optum Inc. (U.S.)
• CareCentrix Inc. (U.S.)
• CVS Health (U.S.)
• KabaFusion (U.S.)
• Promptcare Respiratory (U.S.)
• Baxter (U.S.)
• InfuSystem Holdings, Inc. (U.S.)
• Moog Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• February 2026: KabaFusion and Nautic Partners completed the significant growth investment in KabaFusion. KabaFusion’s clinician-led management team remained significant investors and continued to lead the company.
• December 2025: BioMatrix Infusion Pharmacy acquired Total Infusion Care, a Nevada-based infusion therapy provider serving patients across the western U.S. The transaction was closed on November 2025.
• October 2025: BioMatrix Infusion Pharmacy acquired LUX Infusion, Alaska’s ambulatory infusion center business. The acquisition added three infusion centers and expanded BioMatrix’s national ambulatory infusion footprint.
• September 2025: KabaFusion partnered with Tennr to use AI technology for home infusion care coordination. The collaboration focused on streamlining patient processing, improving operational efficiency, reducing care delays, and enhancing patient outcomes
• April 2025: ICU Medical received U.S. FDA 510(k) clearances for Plum Solo and updated Plum Duo precision IV pumps, along with LifeShield infusion safety software.

REPORT COVERAGE

The U.S. home infusion therapy market analysis encompasses an extensive examination of the market size and projections for all market segments featured in the report. It provides information on the market dynamics and trends that are anticipated to propel the market during the forecast period. It offers insights into crucial elements, such as innovations in products, the regulatory landscape, pipeline analysis, and the introduction of new products. Furthermore, it outlines collaborations, mergers & acquisitions, along with significant advancements in the industry within the market. The forecast report additionally offers a comprehensive competitive landscape with details on market share and profiles of major active participants.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation